Effective drugs used in EGFR-embattled therapies are erlotinib and gefitinib (121, 342), also known as EGFR TKIs, which face resistance during the treatment of advanced-stage NSCLC (95, 343, 344). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.